Incyte Corporation · NASDAQ:INCY
Incyte — Technical Presentation (December 2024)
5 slides from Incyte's technical presentation, December 2024
Slide 1: RWE Spain vs. L-MIND study
RWE Spain vs. L- MIND study Tafasitamab+Lenalidomid in relapsed/refractory diffuse large B-cell lymphoma DE/MJVI/P/24/0099, Stand 12/2024 RWE Spain: Gutiérrez A, et al. Poster 2356 presented at ASH annual meeting 2024. Data on file; L-MIND: Duell J, et al. Haematologica. 2024;109(2):553-566. RWE: re
Slide 2: RWE Spain vs. L-MIND study: Patient Characteristics
RWE Spain vs. L-MIND study Patient Characteristics RWE Spain (efficacy Patient Characteristics L-MIND study2 cohort)1 No. of patients n = 83 n = 80 Median age (range) 78 (47-93) 72 (41-86) ECOG PS >1, n (%) 27 (32 %) 7 (9 %)3 (R-) IPI* 3-5, n (%) 44 (53 %) 40 (50 %) Previous lines, n (%) -1-2 61 (73
Slide 3: RWE Spain vs. L-MIND study: Efficacy
RWE Spain vs. L-MIND study Efficacy RWE Spain1 L-MIND study – 5 yrs Analysis2 A. Gutiérrez, et al., ASH J. Düll, et al., Haematologica 2024 2023 Median FU 21.6 months 60 months No. of patients n = 83 n = 80 ORR / CR 61 % / 42 % 58 % / 41 % Median PFS 10.9 months 11.6 months Median OS 21.8 months 33.
Slide 4: Results VI: Relative dose-intensity
RESULTS VI Relative dose-intensity RDI 70%: median DOR: not - Relative dose-intensity (RDI) reached (Lena): - Median RDI: 74% (9-100) RDI <70%: median DOR: 29 months - Lenalidomide reductions: 48% - Lenalidomide interruptions: 12% P= - Impact of RDI on DOR: 0.037 - RDI 70%: not reached - RDI <70%
Slide 5: Indikation von MINJUVI
Indikation von MINJUVI MINJUVI wird angewendet in Kombination mit Lenalidomid gefolgt von einer MINJUVI Monotherapie für die Behandlung bei erwachsenen Patienten mit rezidiviertem oder refraktärem diffusem großzelligem B-Zell-Lymphom (diffuse large B-cell lymphoma, DLBCL), ür die eine autologe Stamm